(AOF) – During the third quarter of 2022, Implanet’s activity recorded growth of 5%, rising from 1.78 million euros over the same period in 2021 to 1.86 million euros. Despite activity in France still impacted by the problems of shortage of hospital staff, preventing a return to a normal level of activity, the growth observed over the quarter is explained by the increase in turnover in the United States. United by +17%, to 0.48 million euros against 0.41 million euros in the third quarter of 2021.
This increase allowed the return to an annual rate of turnover of 2 million euros per year in this territory. This growth is also marked by the resumption of deliveries to SeaSpine; the acceleration of commercial development in the rest of the world, with growth of 13%, to reach 0.70 million euros against 0.62 million euros over the same period in 2021.
During the first nine months of 2022, activity was multiplied by 1.4, i.e. a growth of 37%, going from 4.38 million euros over the same period in 2021 to 5.97 million euros. This increase can be explained both by the organic growth of the Jazz business (+18%) and by the acquisition of OSD (which generated revenue of 2.21 million euros on first nine months of 2022).
In France, activity stood at 2.49 million euros, i.e. growth of 40% compared to the same period in 2021. Activity in the United States returned to the level observed in 2021 thanks to the good performance recorded in the third quarter of 2022 (+17%), ensuring a turnover of 1.28 million euros over the first nine months of 2022 against 1.30 million euros over the same period in 2021.
In the rest of the world, export activity was multiplied by 1.7, going from 1.27 million euros in 2021 to 2.18 million euros.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.